The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer
| Autor: | Samia A. Shouman, Doaa M Badr, Marwa M. Hussien, Salem E. Salem, Mariam A. Fouad, Hafez F. Hafez, Abdel-Rahman N. Zekri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
lcsh:QH426-470 Colorectal cancer Mrna expression promoter methylation Biochemistry 03 medical and health sciences 0302 clinical medicine survival and progression Promoter methylation Gene expression Genetics medicine Clinical significance cyclooxygenase 2 Gene Original Research biology medicine.disease lcsh:Genetics 030104 developmental biology 030220 oncology & carcinogenesis Cancer research biology.protein gene expression Cyclooxygenase fluoropyrimidine metabolizing |
| Zdroj: | Epigenetics Insights, Vol 14 (2021) Epigenetics Insights |
| ISSN: | 2516-8657 |
| Popis: | Aims: This study investigated the impact of promoter methylation of flouropyrimidine (FP) metabolizing and cyclooxygenase 2 (COX2) genes on their mRNA expression and on the clinical outcome of colorectal cancer (CRC) patients. Methods: Methylation specific-PCR and real time-PCR of thymidylate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and COX2 were performed at baseline and after 3 and 6 months of FP therapy. Pairwise comparisons were conducted between the subgroups of CRC patients. The event free survival (EFS) and the hazard of progression were estimated by univariate and multivariate analyses. Results: At baseline CRC patients, both TS and TP were overexpressed, in spite of the unmethylation of TS and the full methylation of TP genes. Significant downexpression of DPD and COX2 were associated their promoter’s methylation. At the end of FP therapy, TS, DPD and COX2 were overexpressed by 7.52, 2.88 and 3.45 folds, respectively, while TP was downexpressed by 0.54 fold. However, no change was observed in the methylation status of genes with FP therapy. Pairwise comparisons revealed significant difference in the expression and the methylation status of genes according to the clinicopathological characters of CRC patients either at baseline or after FP therapy. The overexpression of DPD and COX2 genes were indicators for a poor EFS of CRC patients. Also, the high level of COX2 expression was found to be significantly correlated with the hazard of progression (HR = 1.73, 95% CI = 1.02-3.03). Conclusion: The promoter methylation of FP metabolizing and COX2 genes has significant impact on the expression and the treatment outcome of CRC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|